The serine protease Omi/HtrA2 was initially regarded as a proapoptotic molecule that proteolyses several proteins to induce cell death. Recent studies, however, indicate that loss of Omi protease activity increases susceptibility to stress-induced cell death. These complicated findings suggest that the protease activity of Omi is involved not only in apoptosis but also in cellular homeostasis. However, the targets which Omi uses to mediate this novel process are unknown. Previously, we showed that WARTS (WTS)/large tumor-suppressor 1 mitotic kinase interacts with the protein/discs-large protein/zonula (PDZ) domain of Omi and promotes its protease activity. We now report that WTS is a substrate for Omi protease activity, thus it is not only a regulator but also a downstream target of this protease. Interaction with Omi PDZ domain is required for WTS to be proteolysed. When caspase-9-deficient mouse embryonic fibroblasts (MEFs) were treated with staurosporine, WTS was proteolysed by activated endogenous Omi without induction of cell death. Therefore, protease activity of Omi and proteolysis of WTS are not necessarily required for cell death. We found that depletion of Omi from HeLa cells results in accelerated cell proliferation despite no significant change in the duration of mitosis. The depletion of WTS showed the same effect on S phase progression. Therefore, WTS proteolytic fragment(s) generated by Omi may act as an inhibitor of G1/S progression. Our data reveal a role for Omi-mediated processing of WTS in negative regulation of cell cycle progression at interphase, suggesting a novel function of Omi other than apoptosis.
Introduction
The serine protease Omi (also known as high temperature requirement (HtrA2)) was identified first as an interactor of mxi2 or presenilin in human cells (Faccio et al., 2000; Gray et al., 2000) Thereafter, Omi was found to interact with XIAP(X-linked inhibitor of apoptosis). As XIAP was thought to be a direct inhibitor of caspases, the apoptotic function of Omi was extensively investigated. Omi mainly localizes at the mitochondria in healthy cells but is released from mitochondria into the cytosol in response to apoptotic stimuli and mediates cell death by two distinct mechanisms (Suzuki et al., 2001; Hegde et al., 2002; Martins et al., 2002; Verhagen et al., 2002) : First, the mature (36-kDa) form of Omi, which is produced by cleavage of its precursor in the N-terminal region, binds to and blocks the activity of XIAP and c-inhibitor of apoptosis proteins (IAPs). Second, the serine protease activity of Omi directly induces cell death without requiring caspase activation. However, the notion that Omi is an apoptosis inducer was challenged by a recent study that used Omi knockout or mutant mice. Omi (prss25) knockout mice showed no reduced rate of cell death but suffered loss of a population of neurons in the striatum (Martins et al., 2004) . Furthermore, a mutation in the protease domain of Omi has been identified as a cause of lethal neuromuscular wasting disorder in mnd2 mice (motor neuromuscular degeneration 2) (Jones et al., 2003) . Loss of Omi protease activity increases the susceptibility to stress-induced cell death in fibroblasts derived from the mice. Based on those findings, Omi is being considered to act on maintenance of mitochondrial homeostasis. Collectively, protease activity is important for Omi to function properly in vivo, however, substrates reported to date are all involved in the apoptotic property of Omi (Yang et al., 2003; Cilenti et al., 2004; Trencia et al., 2004) . Therefore, identification of non-apoptotic substrates of Omi is required to elucidate its physiological functions.
A mammalian homolog of the Drosophila tumorsuppressor protein warts, known as WARTS (or large tumor-suppressor 1 (LATS1)), was identified (Nishiyama et al., 1999; Tao et al., 1999) and found to have functions similar to its activity in Drosophila: mice deficient in WARTS (WTS)/LATS1 develop malignant tumors . WTS encodes a serine-threonine kinase that shares a high degree of sequence homology with members of the myotonic dystrophy protein kinase (DMPK) family, many of which participate in mitotic events. WTS was reported to interact with cdk1 kinase in early mitosis and to inhibit its kinase activity . WTS was also demonstrated to function in the mid phase of mitosis because expression of the kinase-inactive mutant of WTS activates spindle assembly checkpoint to delay the mitotic progression (Iida et al., 2004) . A putative yeast homolog of WTS, dbf2, is known as a component of MEN (mitotic exit network) (Bardin and Amon, 2001) , and WTS has been recently shown to regulate cytokinesis by inhibiting LIMK1 (Yang et al., 2004) . Our recent report showed that WTS also participates in the prevention of re-replication and cell division of postmitotic cells with 4N DNA content (Iida et al., 2004) . Furthermore, genetic screens for tissue growth control molecules in Drosophila have indicated that wts regulates cell proliferation via transcriptional and post-transcriptional control of cyclin E (Tapon et al., 2002; Harvey et al., 2003; Udan et al., 2003; Wu et al., 2003) . All these data suggest that WTS plays multiple roles in cell cycle progression but is not restricted to mitosis. However, the underlying mechanisms by which WTS regulates cell cycle progression are not fully understood.
We previously found that WTS interacts with Omi (Kuninaka et al., 2005) . The C-terminal region of WTS binds directly to the protein/discs-large protein/zonula (PDZ) domain of Omi and enhances its protease activity. We now demonstrate that WTS is not only an activator of Omi protease but also a substrate for its protease activity. Our data indicate that activation of Omi protease is not necessarily required for cell death and that signals mediated by the Omi-WTS interaction regulate cell cycle progression at interphase.
Results

WTS is a substrate of Omi protease in vitro
After learning that WTS interacts with Omi in cells we investigated whether Wts serves as a substrate for the protease activity of Omi (Figure 1a ). The amount of recombinant full-length Wts was reduced by its incubation with bacterially produced recombinant wild-type (wt) Omi in a concentration-dependent manner. In contrast, the protease-inactive mutant Omi (S306A), in which Ser 306 is replaced by Ala, had no effect on the abundance of Wts. Moreover, the serine protease inhibitor N-tosyllysine chloromethyl ketone (TLCK) (Gray et al., 2000) blocked the ability of wt Omi to proteolyse Wts. The Omi-catalysed processing of WTS was accompanied by the appearance of a 70-kDa proteolytic fragment. We also found that WTS was proteolytically processed into the same size fragment (70 kDa) by incubation with endogenous Omi immunoprecipitaed from HEK293 T cell lysates (Figure 1b) .
We next investigated whether the interaction of Omi and WTS is required for proteolysis of WTS. Whereas the Wts DN2 (Figure 1c ) was cleaved by wt Omi in a time-dependent manner in vitro, but not the DN2-DVYV (which also lacks the three C-terminal amino acids and does not bind to Omi (Kuninaka et al., 2005) ) (Figure 1d ). Mature Omi with the PDZ domain mutation Y361A (Figure 1c) , which cannot interact with C-terminus of WTS (Li et al., 2002) , also failed to cleave full-length WTS (Figure 1e ). These results thus indicate that the interaction between the PDZ domain of Omi and the C-terminus of Wts is required for cleavage of WTS by Omi.
WTS is proteolysed by Omi in vivo
To determine whether WTS is a substrate for the Omi protease in intact cells, we first examined the effects of various forms of Omi (Figure 2a ) on the amount of fulllength WTS coexpressed in HEK293 T cells. As a control for both transfection efficiency and cleavage specificity, cells were also transfected with an expression plasmid for the unbound form of WTS (DN2-DVYV). Immunoblot analysis revealed that overexpression of the mature form of Omi (residues 134-458) resulted in a marked decrease in the amount of full-length Wts, whereas the quantity of WTS (DN2-DVYV) remained unchanged ( Figure 2b , lane 4). Overexpression of fulllength Omi also reduced the abundance of WTS (lane 2). In contrast, the S306A mutant form of either full-length Omi or mature Omi did not affect the amount of WTS in the transfected cells (lanes 3 and 5).
Next, we examined the effect of ectopically expressed Omi on endogenous WTS in individual cells. We previously showed that a fraction of endogenous WTS molecules localize to the centrosome during interphase and to the mitotic apparatus during mitosis; the remaining WTS molecules are distributed in the cytoplasm and nucleus throughout the cell cycle (Hirota et al., 2000) . Most Omi molecules localize to the intermembrane space of mitochondria under basal conditions but are released into the cytosol in response to apoptotic stimuli (Suzuki et al., 2001; Hegde et al., 2002; Martins et al., 2002; Verhagen et al., 2002) . Consistent with these prior observations, immunofluorescence analysis revealed that recombinant mature Omi, which lacks a mitochondrial leader sequence, was localized to the cytosol of transfected HeLa cells; whereas full-length Omi was detected in the nucleus and mitochondria (the latter localization being apparent as a punctate pattern of staining in the cytoplasm) (Figure 2c) . Overexpression of the mature form of Omi resulted in a loss of endogenous Wts staining, whereas the S306A mutants of either mature or full-length Omi had no effect on the expression of endogenous Wts (Figure 2c, d) . Overexpression of full-length Omi also resulted in a moderate increase in the percentage of cells with a reduced abundance of endogenous WTS (Figure 2d) , consistent with the results of the immunoblot analysis (Figure 2b ). Together, these results suggest that WTS is a physiological substrate of Omi protease activity in living cells.
Staurosporine-or ultraviolet-induced activation of Omi results in WTS proteolysis Staurosporine (STS) induces the translocation of mature Omi from mitochondria to the cytosol followed by activation (Hegde et al., 2002) . Thus, we examined whether endogenous Omi activated by STS treatment can proteolyse WTS in cells. The abundance of HAtagged, full-length WTS expressed in HeLa cells was reduced by STS treatment in a concentration-dependent manner, whereas WTS (DVYV) levels were not affected ( Figure 3a) . Endogenous full-length WTS was also cleaved by STS treatment, and a serine protease inhibitor TLCK suppressed the cleavage (Figure 3b) , consistent with the results of the in vitro protease assay. When HEK293 cells were treated with STS, we could detect a 70 kDa proteolytic fragment of endogenous WTS (Figure 3c ), which is also comparable to the in vitro cleavage product. Proteolysis of WARTS by Omi protease S Kuninaka et al proteolysis of endogenous WTS during exposure of HeLa cells to STS ( Figure 3d ). It has been reported recently that ultraviolet (UV) radiation also induces activation of Omi (Martins et al., 2002) . We showed that UV radiation-induced cleavage of WTS and that this effect was also blocked by depletion of endogenous Omi in HeLa cells ( Figure 3e ). These observations indicate that WTS is cleaved as a result of its interaction with activated Omi in HeLa cells. Both STS and UV-irradiation are well-known activators of caspases as well as Omi. Moreover, mature Omi promotes activation of effector caspases by inhibiting IAP (Suzuki et al., 2001; Hegde et al., 2002; Verhagen et al., 2002) . To clarify whether the reduction of endogenous WTS is regulated by Omi directly or indirectly, we examined the effect of STS on WTS levels in the presence of the broad caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-(OMe) fluoromethyl ketone (z-VAD-fmk) and Boc-D-fmk. Endogenous WTS in HeLa cells was degraded under conditions in which the cleavage of poly (ADP-ribose) polymerase (PARP), a well-characterized substrate of activated caspases, was inhibited (Supplementary Information, Figure S1 ). These results thus indicate that caspase activation is not required for the proteolysis of WTS during Omi activation.
We previously reported that STS activates the protease activity of Omi, leading to cell death (Kuninaka et al., 2005) . To exclude the possibility that WTS proteolysis induced by STS treatment or mature Omi overexpression is merely a result of cell death, we treated L929 cells with tumor necrosis factor-a (TNF-a) to induce necrosis (Vercammen et al., 1998) and with STS to induce apoptosis. TNF-a, in contrast to STS, is known to induce cell death without the release of mature Omi from mitochondria (Supplementary Information Figure S2 ; van Loo et al., 2002) . While STS-induced WTS proteolysis, TNF-a did not, even though more than 80% of TNF-a-treated cells underwent cell death (Supplementary Information Figure S3) . These data thus support the notion that apoptotic stimuli induce the activation of Omi and the consequent digestion of WTS by a caspase-independent mechanism. 
Proteolysis of WARTS by Omi protease S Kuninaka et al
Protease activity of Omi is not necessarily required for cell death It has been reported that the protease activity of Omi, at least in part, contributes to cell death execution (Yang et al., 2003; Cilenti et al., 2004; Trencia et al., 2004) . We found that WTS can promote the protease activity of Omi to induce cell death (Kuninaka et al., 2005) . However, recent reports using Omi protease mutant or knockout mice indicate that loss of protein or protease activity of Omi sensitizes some types of cell death stimuli, which contradicts the previous findings. We, therefore, investigated whether Omi-mediated proteolysis of WTS plays a role in cell death. We treated mouse embryonic fibroblasts (MEFs) deficient in caspase-9 with STS, which can activate Omi protease (Figure 4a , b). Consistent with previous reports, STS, which is also an activator of mitochondrial cell death pathways, induced cell death in wt MEFs but not in caspase-9-deficient MEFs (Kuida et al., 1998) (Figure 4a ). Interestingly, endogenous WTS was proteolysed in capase-9 knockout MEFs without significant rates of cell death (Figure 4a ), suggesting that WTS is a non-apoptotic substrate of Omi.
To further rule out the possibility that proteases other than Omi may catalyse this WTS cleavage, we examined the abundance of 3 C-terminal amino acids deleted from WTS (DVYV) in caspase-9-deficient MEFs after STS treatment. In contrast to full-length WTS and XIAP which is also known as substrate of Omi (Yang et al., 2003) , expression levels of WTS (DVYV) did not significantly change compared with that of full-length WTS even in the presence of 1 mM STS (Figure 4b , also see Figure 3a Proteolysis of WARTS by Omi protease S Kuninaka et al mutant of WTS was also cleaved by STS-mediated proteolysis (data not shown).
Caspase 9-deficiency has no effect on release of cytochrome-c as well as Omi from mitochondoria after cell death stimuli. If Omi-mediated apoptosis converges on the caspase-9 activation, Omi can cleave WTS without cell death in caspase-9-deficient MEFs. We therefore analysed the sensitivity of caspase-9-deficient MEFs to Omi-mediated cell death. As shown in Figure 4c , we found that caspase-9 KO MEFs are still sensitive to Omi-mediated cell death. Overexpression of mature Omi can induce cell death in caspase-9 KO MEFs but STS-induced activation of endogenous Omi does not (Figure 4a and c) , indicating that WTS is very sensitive substrate of Omi protease and implying function of Omi other than apoptosis through WTS cleavage. Furthermore, we found that TLCK inhibited proteolysis of WTS in HeLa cells treated with STS (Figure 3b ) where cytochrome-c as well as Omi were released from mitochondria and subsequently the effector caspases were activated (PARP cleavage; Supplementary Information, Figure S4 ). These results suggest that effector caspase activation (equal to cell death execution) can be separable from Omi-mediated WTS cleavage. Overall, all these results suggest that proteolysis of WTS is not required for Omi to mediate cell death and, thereby, that protease activity of Omi has functions other than apoptosis.
Effect of Omi on cell cycle progression Given that WTS is known to play important roles in mitotic and postmitotic cell cycle regulation, Omi may be involved in cell cycle progression through the degradation of WTS. To address this hypothesis, we transfected HeLa cells with the siRNA oligo against Omi and analysed the duration of the mitotic phase using time-lapse microscopy. siRNA oligos against Omi as well as WTS effectively downregulates the expression of those proteins from 24 h after transfection and it retained the effect until 72 h after their introduction to HeLa cells ( Supplementary Information, Figure S5 ). There was no significant change in the median time required for cell division between Omi-depleted and control cells (Figure 5a and Supplementary Information, Figure S6 ). Instead, the doubling time (duration of one cell cycle) of Omi-depleted cells decreased by 2-3 h compared to that of control cells (Figure 5b ), suggesting that Omi-depletion induces rapid cell proliferation. The doubling time of HeLa cells under normal culture conditions is about 22 h. Although the siRNA transfection procedure might affect the doubling time to some extent, the shortened doubling time was consistent irrespective of RNAi duration (Figure 5b ). We could also obtain the same result using another siRNA oligo against Omi ( Supplementary Information, Figure S7 ). To further confirm the results of time-lapse microscopy, we examined the BrdU incorporation of these cells. Depletion of Omi resulted in a significant increase in the percentage of cells at the S phase with a concomitant reduction in the fraction of cells at the G1 phase (Figure 5c ). We found that depletion of WTS also showed the same effect on S phase progression (Figure 5c ), which is consistent with the data obtained in fly (Wu et al., 2003) . Another siRNA oligo against WTS showed the same effect (Supplementary Information, Figure S8 ). Based on those findings, we speculated that WTS proteolytic fragment(s) generated by Omi may act as an inhibitor of G1/S progression. This hypothesis was supported by the fact that overexpression of WTS suppressed S phase progression whereas DVYV WTS overexpression showed much less effect (Figure 5d ). Thus, proteolysis of WTS by Omi may negatively regulate cell cycle progression at interphase.
Interaction of Omi with WTS in nucleus
Next, we attempted to clarify where WTS interacts with Omi in a non-apoptotic condition. WTS distributes diffusely throughout the cytoplasm and nucleus (Figure 2c ), and it also localizes to the centrosome during interphase and to the mitotic apparatus during mitosis (Hirota et al., 2000) . On the other hand, Omi possesses a mitochondrial targeting sequence at its N-terminus and is localized predominantly to the intermembrane space of mitochondria (Suzuki et al., 2001; Hegde et al., 2002; Martins et al., 2002; Verhagen et al., 2002) . However, previous studies (Gray et al., 2000) , together with our present result of Omi overexpression in HeLa cells (Figure 2c ), indicate that some fraction of Omi localizes in the nucleus under resting condition. Immunocytochemical analysis of endogenous Omi also showed that it is localized in nucleus as well as mitochondria (Figure 6a ). These data allow us to speculate that Omi interacts with and proteolyses WTS in the nucleus at interphase to play a role in cell cycle control. To examine this possibility, we performed subcellular fractionation and found that both precursor and mature forms of Omi were identified in the nuclear fractions ( Figure 6b , top panel and 6c). Importantly, WTS was shown to preferentially interact with the precursor form of Omi in nuclear extracts prepared from exponentially growing HeLa cells (Figure 6c ). These results are consistent with our hypothesis that Omi participates in non-apoptotic function by interacting with WTS in nucleus.
Discussion
Omi is a member of the family of heat shock endoproteases defined by bacterial HtrA (Pallen and Wren, 1997; Faccio et al., 2000; Gray et al., 2000) . Like the ancestral protease HtrA, Omi harbors a PDZ domain in the C-terminal one-third of its primary structure. The tumor-suppressor WTS binds directly to the PDZ domain of Omi through its C-terminal region and is proteolysed by activated Omi. Our findings indicate that WTS is regarded as an activator, as well as a substrate, of Omi protease. It has been reported that Omi targets several proteins such as IAPs, HAX-1 and ped/pea-15 (Yang et al., 2003; Cilenti et al., 2004; Trencia et al., 2004) (b) Subcellular fractionation. Nuclear extracts were obtained as described previously (Mendez and Stillman, 2000) . Supernatant after hypotonic buffer treatment was used as cytoplasmic fraction.
Lysates were subjected to immunoblot analysis with the indicated antibodies. (c) Omi binds to WTS at nucleus. The nuclear extracts were subjected to immunoprecipitation assay using anti-WTS serum (60) or normal rabbit serum, and then the bound proteins were immunoblotted to anti-Omi antibody (R&D). Rabbit TrueBlot (eBioscience, San Diego, CA, USA) was used as a secondary antibody to quench the signal of IgG heavy chain.
factors, and Omi antagonized the function by their proteolysis to execute cell death. We found that proteolysis of WTS can proceed in caspase-9-deficient MEFs treated with STS, which activates endogenous Omi, although most of these cells were still alive, as described previously (Kuida et al., 1998) . These results indicate that proteolysis of WTS is not necessarily required for cell death. WTS may be a substrate for an Omi-mediated pathway other than apoptotic signaling. We found that WTS must interact with Omi to be proteolszed (Figure 1d and e) . Therefore, binding of these two molecules is important for signal transduction. When the C-terminal three amino acids (Val-Tyr-Val) of WTS are removed it is prevented from associating with Omi (Kuninaka et al., 2005) . As LATS2 (LTS2), another member of the class of mammalian WTS/ LATS1 kinase, has the same three C-terminal amino acids as WTS, it is possible that LTS2 also contributes to the Omi-mediated signaling pathway. However, LTS2 could neither interact with the Omi PDZ domain nor be cleaved by STS-activated Omi protease under our experimental conditions (Supplementary Information, Figure S9 , S10). Recent analysis of target specificity between the PDZ domain and its binding partner has demonstrated that like the extreme C-terminal three peptides the residues at positions -1, -4 and/or -5 of ligands are important for many PDZ interactions (Songyang et al., 1997; Hock et al., 1998) . Given that amino acids at positions -4 and -5 of LTS2 differ from the corresponding locations on WTS (WTS: Arg-AspLeu-Val-Tyr-Val; LTS2: Cys-Gln-Pro-Val-Tyr-Val), the interaction is specific for WTS. Thus, LTS2 is unlikely to participate in the Omi-mediated pathways. The fact that WTS knockout mice can be born while LTS2 knockout mice are embryonic lethal McPherson et al., 2004) also suggests that the two molecules have distinct functions in vivo. Future detailed analysis of functional crosstalk between WTS and LTS2 would be important.
We found that WTS binds to precursor form, but hardly to mature form of Omi in nucleus (Figure 6c ). WTS interacts with Omi PDZ domain through its Cterminus. Although both forms of Omi have PDZ domain, mechanism that mature Omi cannot bind WTS in nucleus still remains to be elucidated. Plausible explanation for this observation is that post-translational modification of mature Omi in nucleus prevents the binding to WTS. Actually, we found that mature form of Omi leaked from mitochondria to nuclear fraction can interact with WTS (data not shown), implying that mature Omi in mitochondria is somewhat different from that in nucleus. Another complexity of our finding is that WTS forms a stable complex with Omi in nucleus (Figure 6c ) although it is cleaved when interacts with Omi (Figure 1a and e) . Intracellular molar ratio of WTS and Omi in HeLa cells is 0.67:1 by our Western blotting data. Structural analysis performed by Li et al. (2002) revealed that Omi functions as trimer, and trimer formation of ligands is required for the activation of Omi protease. According to our calculation, there are two molecules of WTS per one Omi complex, indicating that WTS cannot activate all Omi complexes in HeLa cells. Omi-bound one or two molecules of WTS, which can not fully activate Omi protease, would therefore not be cleaved, resulting in forming a stable complex in cells. Overall, our present data indicate that endogenous interaction between Omi and WTS is not always dependent on apoptotic stimuli. In proliferating cells, precursor form of Omi binds to WTS in nucleus to possibly control the G1/S progression (Figure 6c ). These results suggest that spatiotemporal control of the Omi-WTS interaction is important for coordinated regulation of cell cycle and cell death.
Drosophila wts has been identified as a component of a molecular complex that regulates tissue size (Tapon et al., 2002; Harvey et al., 2003; Udan et al., 2003; Wu et al., 2003) . Organ size during metazoan development is controlled by coordinated regulation of cell proliferation and cell death. Drosophila wts mutants show elevated levels of cyclin E and accelerated proliferation, resulting in tissue overgrowth (Wu et al., 2003) . Consistent with data from flies, we found that depletion of WTS in HeLa cells causes an elevated uptake of BrdU and that its overexpression shows the converse phenomenon (Figure 5c and d) . Knockdown of Omi also leads to accelerated proliferation of cells (Figure 5b and c) , indicating that Omi plays a major role in the pathway of WTS-mediated S phase control. Furthermore, introduction of a mutation at the C-terminus (DVYV), which makes WTS resistant to Omi-mediated proteolysis, abrogates the effect of the full-length WTS on S phase progression. Our results suggest a novel regulation of G1/S progression through the Omi-WTS interaction: WTS binding activates Omi protease, and the activated Omi cleaves WTS to generate fragment(s), which inhibits S phase progression. Our results thus shed light onto a novel function of Omi other than apoptosis. Dysfunction of cell cycle progression may explain the cause of vulnerability to stresses of cells with loss of Omi protease activity in mouse model systems.
Materials and methods
Plasmids and antibodies
All mammalian and bacterial expression plasmids for WTS or Omi were constructed as described previously (Kuninaka et al., 2005) . Rabbit polyclonal antibodies to Wts (C2 and 60) or rat polyclonal antibodies to Omi (RC70) were also generated as previously described (Kuninaka et al., 2005) . Monoclonal antibodies to the FLAG epitope (M2) and to HA (3F10) were obtained from Sigma-Aldrich, St Louis, MO, USA and Roche, Lewis, UK respectively. Other antibodies used in this study included those to a-tubulin (B-5-1-2, SigmaAldrich), to Myc (A14, Santa Cruz Biotechnology, Santa Cruz, CA, USA), to PARP p85 (Promega, Madison, WI, USA), to XIAP (R&D), to Omi/HtrA2 (R&D), to PDI (Stressgen, Ann Arbor, MI, USA), to LaminA/C (Santa Cruz) and to cytochrome-c (Pharmingen, San Diego, CA, USA).
Cell culture and transfection
HeLa, COS-7 and HEK293 cells were grown under an atmosphere of 5% CO 2 at 371C in Dulbecco's modified Eagle's medium (DMEM) -F12 (Sigma) supplemented with 10% heat-inactivated fetal bovine serum without antibiotics. L929 mouse fibrosarcoma cells and MEFs deficient for caspase-9 (Kuida et al., 1998) were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum without antibiotics. Cells were subjected to transient transfection in six-well plates with lipofectamine and Plus reagent (Invitrogen, Carlsbad, CA, USA). Preparation of retrovirus and infection to fibroblasts were performed as described previously (Morita et al., 2000) . Transfection procedures and siRNA oligos used in the RNAi experiments are as described previously (Kuninaka et al., 2005) .
Purification of recombinant proteins and in vitro protease assay The full-length WTS cDNA, amplified by PCR, was subcloned into pFastBac (Invitrogen); the encoded soluble protein was expressed in Sf9 cells and purified to homogeneity. Recombinant Omi proteins were produced in Escherichia coli (BL21) transformed with pRSET (Invitrogen) containing cDNA for full-length Omi (wt) or Omi (S306A). The recombinant hexahistidine-tagged proteins were purified with Ni 2 þ -agarose beads (ProBond, Invitrogen), and were released with nativeimidazole elution buffer (20 mM sodium phosphate (pH 6.0), 500 mM NaCl, 200 mM imidazole). The protein concentration was determined with the BCA protein assay reagent (Pierce, Rockford, IL, USA). We evaluated titer of each antibody against WTS or Omi using the known concentration of the recombinant proteins by Western blot analysis. Immunoblot analysis after adjustment of affinity of each antibody revealed that the molar ratio of Omi to WTS expressed in HeLa cells is about 1:0.67. Therefore, we performed in vitro protease assays with WTS present at a >10-fold molar excess relative to Omi. For IP-protease assay, endogenous Omi proteins were immunopurified from HEK293 T cells. The cell lysates were prepared by incubation for 15 min on ice with lysis buffer (0.5% NP-40, 25 mM Tris-Cl (pH 7.5), 137 mM NaCl, 1 mM ethylenediamine-N,N,N 0 ,N 0 -tetraacetic acid (EDTA), 5% glycerol, 1 mM dithiothreitol, 20 mM b-glycerophosphate, 1 mM sodium vanadate, aprotinin (2 mg/ml), 1 mM 4-(2-aminoethyl)-benzene sulfonyl fluoride hydrochloride, 10 mM leupeptin, 1 mM pepstatin). After centrifugation of the lysate at 14 000 g for 20 min, portions of the supernatant were incubated with Omispecific antibody (RC 70) for 1 h. The protein A Sepharose binding to Omi-antibody complexes was washed with lysis buffer without protease inhibitors and then incubated with purified full-length Wts (2.6 mM) for 1 h at 371C.
Immunocytochemistry
HeLa cells were seeded on 35-mm dishes (5 Â 10 4 cells per dish) the day before transfection with 1 mg of pcDNA3-encoding, C-terminal FLAG-tagged full-length or mature Omi (wt or SA mutant). After 24 h, the cells were fixed with 4% paraformaldehyde/phosphate-buffered saline (PBS) for 15 min, followed by permeabilization with 0.2% Triton X-100/PBS. Cells were incubated and stained with anti-WTS (60) and anti-FLAG (M2) antibodies. This was followed by incubation with fluorescein isothiocyanate-conjugated, anti-rabbit antibody (Bioresource, Cotati, CA, USA) and Texas red-conjugated anti-mouse antibody (Molecular Probes, Carlsbad, CA, USA). The stained cells were mounted with 1,4-diazabicyclo-[2,2,2]-octane/glycerol and were examined with a confocal microscope (FV300; Olympus).
Flowcytometry
The cell cycle profile was determined as described previously (Sudo et al., 2001 ).
Time-lapse video microscopy
HeLa cells transfected with the indicated siRNA oligo were grown in 35-mm Delta-T dishes (Bioptechs Inc., Butler, PA, USA), containing Leibovitz's CO 2 -independent medium (Invitrogen). Time-lapse DIC video was taken as described previously (Nitta et al., 2004) . The duration of mitosis was determined morphologically by time-lapse videomicroscopy; its onset was defined as the time when the cell first became rounded and refractile and the end was defined as the time when the cell divided (cytokinesis).
Subcellular fractionation and Immunoprecipitation
Nuclear extracts were obtained as described previously (Mendez and Stillman, 2000) . In brief, exponentially growing HeLa cells were collected and lysed by Dounce homogenization in hypotonic buffer (20 mM Hepes-KOH (pH 8.0), 5 mM KCl, 1.5 mM MgCl 2 , 5 mM sodium butyrate, 0.1 mM dithiothreitol). Nuclei were collected by centrifugation (10 min, 16 000 g, 41C) and resuspended in nuclear extraction buffer (15 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.4 M NaCl, 10% sucrose, 1 mM DTT). Supernatant of nuclear pellet was used as cytoplasmic fraction. After 30 min incubation of nuclei, soluble fraction (nuclear extract) was obtained by high-speed centrifugation (40 min, 100 000 g, 41C). Obtained nuclear extracts were incubated for 1 h at 41C with 1 ml of normal rabbit serum (control) or anti-WTS (60) serum and then with protein A beads (Pharmacia). The beads were then separated by centrifugation and washed with lysis buffer (0.5% NP-40, 25 mM Tris-Cl (pH 7.5), 137 mM NaCl, 1 mM EDTA, 5% glycerol, 1 mM dithiothreitol, 20 mM b-glycerophosphate, 1 mM sodium vanadate, aprotinin (2 mg/ml), 1 mM 4-(2-aminoethyl)-benzene sulfonyl fluoride hydrochloride, 10 mM leupeptin). The bound proteins were eluted by boiling for 5 min in sodium dodecyl sulfate sample buffer and subjected to immunoblot analysis.
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LATS1, large tumor-suppressor 1; HtrA, high temperature requirement; IAP, inhibitor of apoptosis protein; DMPK, myotonic dystrophy protein kinase; dlg, discs large; z-VADfmk, benzyloxycarbonyl-Val-Ala-Asp-(OMe) fluoromethyl ketone; BAF, BOC-Asp-(OMe) fluoromethyl ketone; STS, staurosporine.
